This study identified clinical risk factors that resulted in the failure of dutasteride (Avodart) add-on treatment to alpha-adrenergic antagonists for patients with lower urinary tract symptoms (LUTS) and benign prostatic hyperplasia (BPH). The authors concluded that an intravesical prostatic protrusion (IPP; the enlargement of the prostate towards the floor of the bladder) of 13 mm or more, a large prostate volume, and severe blockage are risk factors that result in treatment failure in these patients.

This study investigated whether a combination pill given in fixed doses with or without aspirin can reduce the risk of cardiovascular disease events in patients without a previous history of cardiovascular disease. The data showed that a fixed-dose combination treatment strategy with aspirin significantly reduced the risks of cardiovascular disease, heart attacks, stroke, and cardiovascular death in these patients.

This study investigated whether a single blood pressure (BP) pill containing 4 drugs (quadpill) at quarter doses is more effective than the standard dose of a single drug as initial treatment in patients with hypertension. The data showed that a quadpill was safe and more effective in getting BP under control than the standard therapy.

This study looked at the effects of diet and lifestyle changes for people with high blood pressure who did not respond to medication. It found that a four-month counseling program led to significant improvement in diet and exercise, blood pressure, and heart health.

This study investigated if a salt substitute could reduce the risk of stroke and cardiovascular (CV) events in patients with hypertension (high blood pressure). The data showed that the salt substitute reduced the risks of stroke, major CV events, and death from any cause compared to regular salt in patients with hypertension.

This study evaluated the optimal targets of blood pressure (BP) in older patients. It found that lowering systolic BP (SBP; BP when the heart beats) to 110-130 mmHg resulted in a lower risk of heart attack, stroke, or death compared to maintaining an SBP of 130-150 mmHg.

This study determined the percentage of men with benign prostatic hyperplasia (BPH) that still needed BPH medication after surgical therapy for lower urinary tract symptoms (LUTS). The authors concluded that laser enucleation of the prostate (LEP) had the lowest percentage of patients that still needed BPH medication.

This study reviewed the initial management of benign prostatic hyperplasia (BPH).  

This study looked at the effect of blood pressure (BP)-lowering medications on cerebral small vessel disease (CVSD). It found that maintaining systolic blood pressure (SBP; BP when the heart beats) between 110-129 mmHg reduced the progression of white matter hyperdensities, one of the signs of CVSD on brain scans.

This study assessed the effectiveness of Fluxonorm® herbal supplement when combined with standard therapy for lower urinary tract symptoms (LUTS) in patients with benign prostatic hyperplasia (BPH). The authors concluded that the effectiveness of standard therapy was improved by the addition of Fluxonorm® in patients with BPH.